SUMMARY The platelet monoamine oxidase activity (MAO) of 33 patients with epilepsy was compared with a group of neurological patients and a group of normal control subjects. We found that the MAO activity was increased significantly in the epileptic group when compared with the normal. This was not related to anticonvulsant medication. These results could be explained by the effect of epilepsy or anticonvulsant medication on the maturation of platelets.
The role of CNS monoamines in the aetiology of epilepsy is-not clear. The incidence of seizures in susceptible individuals when they take tricyclic antidepressants' or when they are treated with monoamine oxidase inhibitors2 is strong evidence for such an involvement. The observation that oral tyramine can activate pre-existing episodic EEG abnormalities in epileptic patients3, further indicates a possible monoaminergic involvement in this condition. Tyramine is a substance with well-defined indirect sympathomimetic activity, in that it can cause the release and block the re-uptake of noradrenaline and other amines4. Tyramine is also a good substrate for monoamine oxidase (MAO),5 an enzyme found in platelets which are a readily accessible source of the enzyme in man. One possible explanation of the findings of Swash et a13 is that tyramine metabolism is abnormal in patients with epilepsy, so we have studied MAO activity in platelets from such patients.
Patients and methods
Three groups were studied. The first group contained 33 patients with epilepsy (16 men and 17 women), average age 35 years. The second group included 22 control neurological patients (11 men and 11 women), average age 31 years. Finally, 19 normal control subjects (nine men and 10 women) with an average age of 35 years were studied. The patients with epilepsy all had a long-standing seizure disorder mainly arising in the temporal lobe.
Eight millilitres of venous blood were collected from each subbject into tubes treated with EDTA. The blood was then mixed with 8 ml of a solution containing 9 g/Il of NaCl and 20 g/l of EDTA.
The mixture was centrifuged at 1000 g for 15 min and the platelet rich plasma was carefully removed, avoiding contamination with red blood cells. This plasma was then centrifuged at 2400 g for 15 min and the supernatant was discarded. The platelets were then resuspended in 1 ml 0-3M sucrose and centrifuged again at 2400 g for 15 min. The supernatant was carefully aspirated and discarded, and the platelets resuspended in 1 ml 0-3M sucrose, and stored at -20°C. The identity of the source of the blood samples was known only to one of us (DFS) who collected them but who did not take part in the purification of the platelets, or in the measurement of enzyme activity.
Platelet MAO activity was measured using kynuramine as substrate6 7. The platelets were gently thawed, and then suspended using a Potter-Elvehjem tissue homogeniser. Duplicate 100 ILI samples were used for determination of enzyme activity and protein. 8 The results arexpressed as nmoles of product (4-hydroxyquinoline) formed/mg of protein/30 min incubation period.
Results
The MAO activity of platelets from patients with epilepsy was found to be significantly increased compared with that of normal subjects, and this was the case for both men and women (table 1) . However, in the epileptic groups as a whole, there were no significant differences in platelet MAO activity when five other parameters were Platelet MAO was significantly increased in men with neurological conditions other than epilepsy when compared with normal men, which contrasts with similar female groups between whom there was no significant difference. The MAO activity in blood platelets of normal women was significantly greater than that of normal men, who form a particularly homogeneous group.
Discussion
The importance of increased platelet MAO activ(ity in epileptic patients compared with control subjects is not immediately obvious, especially as the clinical features of the condition do not relate to MAO activity. Our 
